Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With a Novel Form of Anaplerosis

Key facts

Sponsor

The University of Queensland

Principal Investigator

David Coman, MBBS FRACP

Queensland Children's Hospital

Intervention

Triheptanoin(dietary_supplement)

Enrollment

30 enrolled

Eligibility

All sexes

Timeline

2022 – 2023

Study locations (1)

• Queensland Children's Hospital, Brisbane, Queensland, Australia

Collaborators

National Health and Medical Research Council, Australia

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Ataxia-telangiectasia

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGPHASE3NCT06673056
  A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T)
  IntraBio Inc
• ACTIVE NOT RECRUITINGPHASE2NCT04870866
  NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia
  University Hospital, Akershus

See all trials for Ataxia-telangiectasia →